18-Fluorodeoxyglucose Positron Emission Tomography Predicts Recurrence in Resected Pancreatic Ductal Adenocarcinoma

J Gastrointest Surg. 2018 Feb;22(2):279-287. doi: 10.1007/s11605-017-3627-3. Epub 2017 Nov 8.

Abstract

Background: We aimed to determine whether treatment should be stratified according to 18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) maximum standardized uptake values (SUVmax) in pancreatic ductal adenocarcinoma.

Methods: Patients who underwent preoperative 18F-FDG PET/CT between 2006 and 2014 (n = 138) were stratified into high (≥ 4.85) and low (< 4.85) PET groups. The clinicopathological characteristics and prognostic outcomes were analyzed retrospectively.

Results: The primary tumor SUVmax was positively correlated with preoperative CA19-9 levels (P < 0.001). The high PET group failed to achieve postoperative CA19-9 normalization (P = 0.014). Disease-specific (P < 0.001), recurrence-free (P < 0.001), liver recurrence-free (P < 0.001), and peritoneal recurrence-free (P = 0.020) survivals were significantly shorter in the high PET group. The primary tumor SUVmax was an independent predictive risk factor for liver metastasis (hazard ratio 3.46, 95% confidence interval 1.61-7.87; P = 0.001) and peritoneal recurrence (hazard ratio 3.36, 95% confidence interval 1.18-10.89; P = 0.023).

Conclusions: Surgical resection failed to achieve CA19-9 normalization in the high PET group and distant recurrence was frequent. This suggests the potential for residual cancer at distant sites, even after curative resection. Stronger preoperative systemic chemotherapy is preferred for the high PET group patients.

Keywords: Pancreatic neoplasm; Positron emission tomography; Prognosis; Recurrence.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • CA-19-9 Antigen / blood
  • Carcinoma, Pancreatic Ductal / blood
  • Carcinoma, Pancreatic Ductal / diagnostic imaging*
  • Carcinoma, Pancreatic Ductal / secondary*
  • Carcinoma, Pancreatic Ductal / surgery
  • Disease-Free Survival
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Liver Neoplasms / secondary*
  • Male
  • Middle Aged
  • Pancreatic Neoplasms / blood
  • Pancreatic Neoplasms / diagnostic imaging*
  • Pancreatic Neoplasms / pathology*
  • Pancreatic Neoplasms / surgery
  • Peritoneal Neoplasms / secondary*
  • Positron Emission Tomography Computed Tomography
  • Positron-Emission Tomography*
  • Predictive Value of Tests
  • Preoperative Period
  • Radiopharmaceuticals
  • Retrospective Studies
  • Survival Rate

Substances

  • CA-19-9 Antigen
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18